Carol Moore Biography and Net Worth

SVP of Cerus

Ms. Moore was promoted to Senior Vice President, Regulatory Affairs, Quality, and Clinical in 2013. She has been at Cerus since 2008, previously serving as Vice President, Regulatory Affairs, Quality and Clinical. Prior to joining Cerus, she served as Vice President, Worldwide Regulatory Affairs at Bayer Corporation. Ms. Moore was with Bayer for over 30 years, during which she was involved with registration and regulatory compliance of Bayer’s biological and biotech products, health policy, and strategic planning.

What is Carol Moore's net worth?: The estimated net worth of Carol Moore is at least $701,590.89 as of March 13th, 2024. Ms. Moore owns 490,623 shares of Cerus stock worth more than $701,591 as of March 26th. This net worth approximation does not reflect any other investments that Ms. Moore may own. Learn More about Carol Moore's net worth.
How do I contact Carol Moore?: The corporate mailing address for Ms. Moore and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at ir@cerus.com. Learn More on Carol Moore's contact information.
Has Carol Moore been buying or selling shares of Cerus?: Carol Moore has not been actively trading shares of Cerus over the course of the past ninety days. Most recently, Carol Moore sold 20,619 shares of the business's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $2.02, for a transaction totalling $41,650.38. Following the completion of the sale, the senior vice president now directly owns 490,623 shares of the company's stock, valued at $991,058.46. Learn More on Carol Moore's trading history.
Who are Cerus' active insiders?: Cerus' insider roster includes Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.
Are insiders buying or selling shares of Cerus?: In the last year, Cerus insiders bought shares 2 times. They purchased a total of 5,000 shares worth more than $9,675.00. In the last year, insiders at the biotechnology company sold shares 15 times. They sold a total of 511,140 shares worth more than $816,701.40. The most recent insider tranaction occured on March, 13th when COO Vivek K Jayaraman sold 29,985 shares worth more than $43,478.25. Insiders at Cerus own 3.4% of the company. Learn More about insider trades at Cerus.
Information on this page was last updated on 3/13/2025.

Carol Moore Insider Trading History at Cerus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2024	Sell	20,619	$2.02	$41,650.38	490,623
3/13/2023	Sell	13,078	$2.80	$36,618.40	407,598
3/14/2022	Sell	28,513	$5.04	$143,705.52
1/3/2022	Sell	19,059	$7.00	$133,413.00
11/5/2021	Sell	110,000	$7.94	$873,400.00
3/15/2021	Sell	29,331	$6.38	$187,131.78
8/12/2020	Sell	21,621	$6.88	$148,752.48	141,751
6/25/2020	Sell	130,000	$7.00	$910,000.00	241,751
6/1/2020	Sell	30,025	$6.50	$195,162.50	141,751
3/17/2020	Sell	26,684	$3.59	$95,795.56
9/16/2019	Sell	30,000	$5.33	$159,900.00
3/13/2019	Sell	10,886	$6.01	$65,424.86
6/5/2018	Sell	75,000	$6.72	$504,000.00	46,363
5/11/2018	Sell	60,841	$6.26	$380,864.66	60,841
3/13/2018	Sell	2,623	$5.05	$13,246.15
3/14/2017	Sell	2,377	$4.15	$9,864.55

Carol Moore Buying and Selling Activity at Cerus

Cerus Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Today's Range

Now: $1.43

$1.40

$1.48

50 Day Range

MA: $1.70

$1.39

$2.15

2 Week Range

Now: $1.43

$1.38

$2.54

Volume

1,270,175 shs

Average Volume

1,221,488 shs

Market Capitalization

$265.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56